Clinical Trial Update: NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

The Phase 2 trial of NovoTTF-100A Therapy for refractory CNS-involved small cell lung cancer (including brain metastases) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastasis
• Small Cell Lung Cancer

Drugs mentioned

• NovoTTF-100A Therapy

Snippet

Sponsor: John Villano | Conditions: Small Cell Lung Cancer, Brain Metastasis | Phase 2 | Status: WITHDRAWN